Bioavailability and pharmacokinetic profile of balovaptan, a selective, brain-penetrant vasopressin 1a receptor antagonist, in healthy volunteers
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Bioavailability and pharmacokinetic profile of balovaptan, a selective, brain-penetrant vasopressin 1a receptor antagonist, in healthy volunteers
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume -, Issue -, Pages 1-9
Publisher
Informa UK Limited
Online
2021-06-28
DOI
10.1080/13543784.2021.1948009
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder
- (2020) Patrick Schnider et al. JOURNAL OF MEDICINAL CHEMISTRY
- A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism
- (2019) Karen J. Parker et al. Science Translational Medicine
- A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder
- (2019) Federico Bolognani et al. Science Translational Medicine
- How do hypothalamic nonapeptides shape youth’s sociality? A systematic review on oxytocin, vasopressin and human socio-emotional development
- (2018) Nuno Torres et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- Autism Spectrum Disorder: Classification, diagnosis and therapy
- (2018) Samata R. Sharma et al. PHARMACOLOGY & THERAPEUTICS
- Social Skills Deficits in Autism Spectrum Disorder: Potential Biological Origins and Progress in Developing Therapeutic Agents
- (2018) Richard E. Frye CNS DRUGS
- Replicative genetic association study between functional polymorphisms in AVPR1A and social behavior scales of autism spectrum disorder in the Korean population
- (2017) So Young Yang et al. Molecular Autism
- A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder
- (2016) Daniel Umbricht et al. NEUROPSYCHOPHARMACOLOGY
- Analysis of the impact of controlled release formulations on oral drug absorption, gut wall metabolism and relative bioavailability of CYP3A substrates using a physiologically-based pharmacokinetic model
- (2015) Andrés Olivares-Morales et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Treatment non-adherence in pediatric long-term medical conditions: systematic review and synthesis of qualitative studies of caregivers’ views
- (2014) Miriam Santer et al. BMC Pediatrics
- Global Prevalence of Autism and Other Pervasive Developmental Disorders
- (2012) Mayada Elsabbagh et al. Autism Research
- Vasopressin selectively impairs emotion recognition in men
- (2011) Florina Uzefovsky et al. PSYCHONEUROENDOCRINOLOGY
- Functionality of promoter microsatellites of arginine vasopressin receptor 1A (AVPR1A): implications for autism
- (2011) Katherine E Tansey et al. Molecular Autism
- Improving Medication Adherence in Chronic Pediatric Health Conditions: A Focus on ADHD in Youth
- (2010) Anil Chacko et al. CURRENT PHARMACEUTICAL DESIGN
- The Challenge of Translation in Social Neuroscience: A Review of Oxytocin, Vasopressin, and Affiliative Behavior
- (2010) Thomas R. Insel NEURON
- Association study between single nucleotide polymorphisms in promoter region of AVPR1A and Korean autism spectrum disorders
- (2010) So Young Yang et al. NEUROSCIENCE LETTERS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started